The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.0M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 695K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

26 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Identification of novel benzimidazole series of potent and selective ORL1 antagonists.EBI
Banyu Tsukuba Research Institute
Cyclohexylmethylpiperidinyltriphenylpropioamide: a selective muscarinic M(3) antagonist discriminating against the other receptor subtypes.EBI
Banyu Tsukuba Research Institute
Isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists.EBI
Banyu Tsukuba Research Institute
The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators.EBI
Banyu Tsukuba Research Institute
Discovery and structure-activity relationships of a novel class of quinazoline glucokinase activators.EBI
Banyu Tsukuba Research Institute
Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.EBI
Banyu Tsukuba Research Institute
Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators.EBI
Banyu Tsukuba Research Institute
Synthesis and biological evaluation of imidazole derivatives as novel NOP/ORL1 receptor antagonists: exploration and optimization of alternative pyrazole structure.EBI
Banyu Tsukuba Research Institute
Structure-activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy.EBI
Banyu Tsukuba Research Institute
Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators.EBI
Banyu Tsukuba Research Institute
Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators.EBI
Banyu Tsukuba Research Institute
Identification of novel and potent 2-amino benzamide derivatives as allosteric glucokinase activators.EBI
Banyu Tsukuba Research Institute
Syntheses and structure-activity relationships of novel, potent, and selective trans-2-[3-oxospiro[isobenzofuran-1(3H),1'-cyclohexan]-4'-yl]benzimidazole NPY Y5 receptor antagonists.EBI
Banyu Tsukuba Research Institute
Design, syntheses, and structure-activity relationships of novel NPY Y5 receptor antagonists: 2-{3-Oxospiro[isobenzofuran-1(3H),4'-piperidin]-1'-yl}benzimidazole derivatives.EBI
Banyu Tsukuba Research Institute
Novel ORL1-selective antagonists with oral bioavailability and brain penetrability.EBI
Banyu Tsukuba Research Institute
Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9.EBI
Banyu Tsukuba Research Institute
Design, synthesis, and biological evaluation of indole derivatives as novel nociceptin/orphanin FQ (N/OFQ) receptor antagonists.EBI
Banyu Tsukuba Research Institute
Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity.EBI
Banyu Tsukuba Research Institute
N-acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist.EBI
Banyu Tsukuba Research Institute
Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B.EBI
Banyu Tsukuba Research Institute
A new class of type I protein geranylgeranyltransferase (GGTase I) inhibitor.EBI
Banyu Tsukuba Research Institute
Discovery of a novel CCR3 selective antagonist.EBI
Banyu Tsukuba Research Institute
Synthesis and biological activities of NB-506 analogues modified at the glucose group.EBI
Banyu Tsukuba Research Institute
Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506.EBI
Banyu Tsukuba Research Institute
Cyclic sulfolanes as novel and high affinity P2 ligands for HIV-1 protease inhibitors.BDB
Merck Research Laboratories
Design and synthesis of potent C(2)-symmetric diol-based HIV-1 protease inhibitors: effects of fluoro substitution.BDB
Linkoping University